TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) 3-Year Revenue Growth Rate : 12.70% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is TEYI PHARMACEUTICAL GROUP CO 3-Year Revenue Growth Rate?

TEYI PHARMACEUTICAL GROUP CO's Revenue per Share for the three months ended in Mar. 2024 was ¥0.39.

During the past 12 months, TEYI PHARMACEUTICAL GROUP CO's average Revenue per Share Growth Rate was -10.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of TEYI PHARMACEUTICAL GROUP CO was 19.30% per year. The lowest was -5.80% per year. And the median was 10.60% per year.

Competitive Comparison of TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate falls into.

TEYI PHARMACEUTICAL GROUP CO 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

TEYI PHARMACEUTICAL GROUP CO 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of TEYI PHARMACEUTICAL GROUP CO's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TEYI PHARMACEUTICAL GROUP CO LTD (SZSE:002728) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

Industrial Park pit, Guangdong Province, North, Taishan, CHN

Website

http://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company. It engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical drugs and raw materials in China. The main pharmaceutical preparation products cover a cough and phlegm, kidney, anti-infection, cardiovascular and digestive system. The main preparation products include Zhikebao Tablet, Jinqi Shenqi Tablet, Pharyngitis Tablet, and Erythromycin Enteric-coated Tablets.

Executives

Zhang Yong Zhao	Executives
Chen Xi Liang	Directors, Directors, and Executives
Xu Shao Hua	Securities Affairs Representative
Xu Wei Gao	Director
Xu Song Qing	Directors, executives
Liu Guang Tao	Executives
Du Yong Chun	Supervisors
Huang Yan Ling	Executives
Chen Guang Ting	Supervisors

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Headlines

No Headlines